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ABSTRACT
The human platelet-derived growth factor (PDGF) B
chain precursor is usually translated from a 3.5 kb
c-sisIPDGF B gene transcript. The first exon of the
c-sis gene contains the code for the signal peptide of
the PDGF B chain precursor, preceded by a 1 kb long
untranslated sequence with potent translation inhibi-
tory activity. In this paper we show that a novel 2.6 kb
c-sis mRNA present in the human choriocarcinoma
cell line JEG-3 initiates at an alternative exon 1, which
we refer to as exon 1a. The 90 bp long exon la is
located in the center of the first intron of the gene. It
coincides with a very pronounced DNase-l-hyper-
sensitive site and is preceded by a functional pro-
moter. Of the three ATG codons present in exon 1 a, the
third one perfectly matches the criteria of a consensus
start codon. It initiates an open reading frame that is
continuous with the code for the PDGF B chain
precursor but lacks the code for a signal peptide. We
conclude that this novel 2.6 kb c-sis mRNA species
lacks the strong translation inhibitory potential of the
regular exon 1 and contains the code for a PDGF B-like
protein that may be targeted to the cell nucleus.
INTRODUCTION
The human c-sis gene encodes the precursor of the platelet-
derived growth factor (PDGF) B chain (1-5), a potent growth
factor for cells of mesenchymal origin. The gene is located on
human chromosome 22 (6,7). It consists of seven exons, which
span -22 kb (8,9). Together the exons form an mRNA of 3.5 kb,
of which 2.8 kb consist of non-translated sequences. Exon 1
contains a 1 kb long 5'-untranslated sequence with a strong
translation inhibitory potential (10-12) and, in addition, codes for
the signal peptide. Exons 2-6 code for the major part of the
PDGF B chain precursor, whereas exon 7 consists entirely of a
1.6 kb long 3'-untranslated sequence (8,9). In the endoplasmic
reticulum (ER), the 28 kDa PDGF B chain precursor undergoes
N-linked glycosylation and dimerizes with otherB and/orA chain
precursors (13-17). The B chain precursors are proteolytically
processed in the Golgi system at their N- and C-termini, which
results in the loss of the N-linked carbohydrate. Finally, PDGF B
EMBL accession nos X83705 and X83706
chains are secreted as part of 30 kDa AB or BB dimers, whereas
24 kDa BB dimers remain cell associated and are degraded in
lysosomes (16,17).
The human c-sis gene is transcribed in specific cell types, such
as vascular endothelial cells (18), macrophages (19), activated
monocytes (20), placental cytotrophoblasts (21) and bone marrow
megakaryocytes (22). Furthermore, the gene is transcribed in
several types of transformed cells (e.g. 23,24). The full length
3.5 kb c-sis transcript is found in most human cell types expressing
the gene, but smaller transcripts have been described that hybridize
under stringent conditions with c-sis or v-sis probes (18,23,
25-29). Among these, an -2.6 kb long transcript has been
described most often. Fen and Daniel (29) provided evidence that
a 2.8 kb c-sis transcript expressed in human umbilical vein
endothelial cells (HUVEC) lacks a major part of c-sis exon 1 and
initiates at 15 nucleotides upstream of the PDGF B translation
initiation codon. Since the code for the PDGF B chain precursor is
presumably not affected in the 2.8 kb transcript, the main
difference compared with the 3.5 kb mRNA would be the absence
of the translation inhibitory capacity of the 5'-untranslated region
(10-12). Therefore, it was predicted that the 2.8 kb transcript
would be much more efficiently translated than the 3.5 kb mRNA
(29).
A 2.6 kb c-sis mRNA species expressed in human choriocarci-
noma cell line JEG-3 was also shown to lack exon 1-derived
sequences and was suggested to be antisense to the major 3.5 kb
c-sis mRNA (28). Indeed, in JEG-3 cells the regular c-sis
promoter does not coincide with a DNase-I-hypersensitivity
(DH) site (30), which strongly suggests that the promoter is not
active in these cells. However, the presence of a DH site at the
3'-end of the first exon in JEG-3 cells (30) suggests that the 2.6 kb
c-sis transcript could be derived from an alternative promoter,
corresponding with the start site of the 2.8 kb c-sis mRNA in
vascular endothelial cells (29). When we performed primer
extension and nuclease S I experiments, similar to those described
by Fen and Daniel (29), on RNA isolated from JEG-3 cells, we
found that the 2.6 kb c-sis mRNA has the same orientation as the
3.5 kb mRNA and that its 5'-end extends 90 nucleotides (nt)
upstream ofexon 2-derived sequences. Surprisingly, the 5'-end of
the 2.6 kb transcript turned out to be different from the 3'-end of
the regular c-sis exon 1. These results prompted us to map the
2.6 kb c-sis mRNA from JEG-3 cells in more detail, which led to
the discovery that the transcript initiates at an alternative exon
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located within c-sis intron 1. Our results indicate that in JEG-3
cells the c-sis gene uses a hitherto unknown expression pathway
that may not only affect the translation efficiency of the c-sis
mRNA, but also the structure and cellular location of its protein
product.
MATERIALS AND METHODS
Cell culture
Cell lines K562, JEG-3, JAR, HeLa and T24 were all from the
American Type Culture Collection (Rockville, MD). Cells were
grown in Dulbecco's modified Eagle's medium supplemented with
10% fetal calf serum and 125 U/ml streptomycin and 125 U/ml
penicillin. Megakaryocytic differentiation of K562 cells was
induced by addition of 12-O-tetradecanoylphorbol 13-acetate
(TPA; Sigma) to the culture medium (final concentration, 2 ng/ml).
Isolation and Northern blot analysis of RNA
Total cellular RNA was isolated according to the LiCl/urea
method (31). RNA was glyoxylated, electrophoresed in 1%
agarose gels containing 10mM Na2HPO4, pH 7.0 and transferred
to Hybond-N filters (Amersham, UK) as described (32). RNA
was hybridized overnight in 0.5M Na2HPO4, pH 7.2, 1% bovine
serum albumin, 7% SDS, 1 mM EDTA at 650C with 32P-labeled
DNA probes. Filters were washed at 65°C in 0.1 M Na2HPO4,
0.5% SDS, 1 mM EDTA and exposed to Kodak XAR-5 X-Ray
film with two Cronex intensifying screens (Du Pont).
Plasmids and probes
A 2 kb BamHI fragment that contains sequences from c-sis exons
1-7 was isolated from human c-sis cDNA clone pSM- 1, which
was kindly provided by Dr S. T. Josephs. A 2 kb EcoRI-HindIll
fragment containing all c-sis exon 1-derived sequences was
isolated from pAO121. A 1.45 kb BamHI fragment that contains
the 3' half of exon 7 was isolated from human c-sis cosmid clone
ALLW-1283-C121. The 0.6 kb PstI-BglII fragment of pSM-l
was cloned into pGEM-3Zf(+) and was used as the probe for
nuclease SI analysis. The 0.35 kb PstI-KpnI fragment ofpAO78
was used as a probe for DH site mapping. pAO78 contains the
8 kb BamHI fragment ofALLW-1283-CI21 cloned into pBR322.
pAO152 contains the 2 kb HindIII-BamHI fragment of
ALLW-1283-C121 cloned into pAT153. Genomic c-sis clones
pAO70, pAO121 and ALLW-1283-C121 (33) and pAO154 (34)
have been described earlier. Human PDGF A cDNA clone 13.1
was kindly provided by Dr C. Betsholtz. All DNA probes used in
Southern blot and Northern blot analyses were labeled with 32p
by the random primer labeling method (35) to specific activities
of 108-109 c.p.m./jg DNA.
The reporter gene construct psis-1 121+43CAT has been
described earlier (30). pSuperCAT is a promoterless chloram-
phenicol acetyltransferase (CAT) gene vector. pAltsis(s)CAT and
pAltsis(a)CAT were made by cloning the 0.22 kb DdeI fragment
ofpAO78 in the sense (s) or antisense (a) orientation into the SniaI
site of pSuperCAT. pSV2CAT was described earlier (36).
pCH110 (Pharmacia LKB) contains the ,B-galactosidase gene
Primer extension analysis
cDNA was synthesized from 30 ,ug JEG-3 and JAR RNA using
the 32P-end-labeled exon 2-derived antisense oligonucleotide
5'-(GTG CAG CAG GCG TTG GAG ATC ATC AAA GGA
GCG GA)-3' as a primer, essentially as was described by Fen and
Daniel (29). Primer extension products were electrophoresed in
a 6% sequencing gel and exposed to Kodak XAR5 X-ray film for
2 weeks with two intensifying screens. The same exon 2-derived
oligonucleotide was used as a primer to generate a nucleotide
sequence ladder (37) of c-sis cDNA clone pSM-1, which served
as a marker for the primer extension analysis.
Nuclease Si analysis
Nuclease S1 analysis was done as described earlier (38). The
nuclease SI probe (see Fig. 3A) was labeled with 32P according
to Sanger et al. (37) and purified by electrophoresis in a 6%
sequencing gel. RNA from TPA treated K562 cells (50 jig) and
JEG-3 cells (250 jg) was hybridized overnight at 40°C with
32P-labeled probe. Treatment with nuclease S1 (final concentra-
tion 2 U/jl) was for 60 min at 37°C. Protected fragments were
electrophoresed in a 6% sequencing gel and exposed to Kodak
XAR-5 film. The dideoxy nucleotide sequence ladder of the SI
probe (37) was used as a molecular weight marker.
cDNA cloning
Polyadenylated RNA from JEG-3 cells was purified by
oligo(dT)-cellulose affinity chromatography. cDNA synthesis
and amplification were according to the protocol of the 5'-Ampli-
FINDER RACE Kit (Clontech), which is based on the single-
strand-ligation-to-single-stranded-cDNA (SLIC) method according
to Dumas et al. (39). cDNA was synthesized from 2 jg
polyadenylated RNA using c-sis exon 6-specific antisense
oligonucleotide 5'-(GTC ACC CGA GTT TGG GGC GT)-3' as
a primer. Upon ligation of the AmpliFINDER Anchor to its 3'
end, the cDNA was amplified using an oligonucleotide comple-
mentary to the AmpliFINDER Anchor Primer and a nested c-sis
exon 5-specific antisense oligonucleotide 5'-(CTC GCT GCT
CCT GGG AAC CC)-3'. The cDNA was amplified in 35 cycles:
denaturation was for 45 s at 94°C, annealing for 45 s at 60°C and
synthesis for 2 min at 72°C. The resulting 600 bp cDNA fragment
was cloned into the SmaI site of pGEM-3Zf(+), yielding
pCORDI.
Nucleotide sequence analysis
DNA fragments were subcloned into pGEM-3Zf(+) and nucleo-
tide sequences were determined according to the dideoxy chain
termination method of Sanger et al. (37). Sequence data were
recorded, edited and compared using IntelliGenetics Suite
software. The cDNA sequence ofpCORDl (EMBL accession no.
X83705) and the genomic DNA sequence of the alternative exon
la (accession no. X83706) were submitted to the EMBL data
library.
Mapping ofDH sites and Southern blot analysis
Nuclear isolations, DNase I digestions and chromosomal DNA
purifications were all performed as previously described (30).
Purified DNA (25 jg) was digested to completion with KpnI
driven by the SV40 promoter. (Gibco Laboratories, Grand Island, USA), extracted once with
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Figure 1. Northern blot analysis of c-sis mRNA species. Total RNA isolated
from JEG-3 (J), HeLa (H) and T24 (T) cells was hybridized with cDNA clone
pSM-1 containing sequences derived from all seven c-sis exons (A), with
genomic clone pA0121 containing the entire c-sis exon 1 (B), with a 1.45 kb
genomic fragment containing the 3' end of c-sis exon 7 (C) and with PDGF A
cDNA clone 13.1 (D). JEG-3 and HeLa lanes contain 10 jg ofRNA; T24 lanes
contain 5 ,ug of RNA.
phenol and chloroform, precipitated with ethanol and dissolved
in 20 gl of H20. The Hindlll fragments of phage X (400 ng/lane)
and the HaeIII fragments of phage 4X174 (200 ng/lane) were
added to each sample as internal molecular size markers. DNA
samples were electrophoresed in 1% agarose gels and transferred
to Hybond-N filters according to the Amersham protocol. DNA
was hybridized overnight in 0.75 M NaCl, 75 mM sodium citrate,
0.1% SDS, 0.1% Ficoll, 0.1% bovine serum albumin, 0.1%
polyvinylpyrrolidone, 100 gg/ml herring sperm DNA at 680C
with 32P-labeled DNA probes. Filters were washed at 680C in 15
mM NaCl, 1.5 mM sodium citrate, 0.1% SDS, then exposed to
X-ray film with two intensifying screens. For genomic localiz-
ation of the alternative exon la, subcloned c-sis fragments were
isolated according to standard protocols (32) and electrophoresed
in a 1% agarose gel. Southern blot analysis was performed as
described above using the 32P-labeled 60 bp EcoRI-AvaI
fragment of c-sis cDNA clone pCORDl as a probe.
exon-1
exon-2
Figure 2. Primer extension analysis of the 2.6 kb c-sis mRNA. Total RNA
derived from choriocarcinoma cell lines JEG-3 and JAR was hybridized with
a c-sis exon 2-specific oligonucleotide and the primer was extended using
reverse transcriptase. The size of the single extension product is indicated. The
sequence ladder was generated by dideoxy nucleotide sequence analysis of
c-sis clone pSM-1 using the same exon 2-specific primer. The boundary
between exon 2- and exon 1-derived sequences is indicated by the arTow on the
left.
Electropermeations and CAT assays
Supercoiled plasmid DNA was purified by CsCl gradient
centrifugation (32) and quantitated by means of both ethidium
bromide staining and spectrophotometric measurement. Cells
(3-5 x 107) were electropermeated with 10 ,ug pCH110 and 10
pmol CAT construct as previously described (30). Cells were
harvested 48 h after electropermeation. Cell lysates were
prepared (32) and the protein content of each lysate was
determined in a protein assay (BioRad). Fixed amounts of protein
were tested for P-galactosidase activity (40) and, subsequently,
amounts of protein corresponding to equal [.-galactosidase
activity were assayed for CAT activity (36). Radioactive spots
were quantitated by measuring in a liquid scintillation counter,
from which the percentage acetylated chloramphenicol could be
determined.
RESULTS
The 5'-end of a 2.6 kb c-sis mRNA species is derived
from an alternative exon
A representative Northern blot analysis, using a probe that
contains sequences derived from all seven c-sis exons, demon-
strates the cell-type specific expression of three c-sis mRNA
/T_ _ I A\ A _ n 1_1i -.2_-_ XT A :
expressed in choriocarcinoma-derived JEG-3 cells, whereas
bladder carcinoma-derived T24 cells express the 3.5 kb, a 3.0 kb
and a 2.6 kb transcript. Cervix carcinoma-derived HeLa cells
express the 3.5 kb and a 3.0 kb species. A parallel Northern blot
analysis using a genomic probe that contains only c-sis exon 1
(Fig. IB) shows that the 2.6 kb transcript does not hybridize with
exon 1-derived sequences. The 3.0 kb transcript hybridizes with
the exon 1 probe, but not as well as with the cDNA clone pSM-1
(Fig. IA and B), which suggests that it lacks a significant part of
exon 1. The hybridization signals obtained with a probe that
contains only sequences derived from the 3'-end of the 1.6 kb
long exon 7 (Fig. IC) are comparable with those obtained with
pSM- 1 (Fig. IA), suggesting that the different sizes of the three
transcripts do not result from alternative polyadenylation. North-
ern blot analysis with additional exon-specific probes indicated
that the 2.6 kb transcript also contains sequences derived from
c-sis exons 5 and 6 and from the 5'-end of exon 7 (data not
shown). We conclude that the 3.0 kb c-sis mRNA expressed in
HeLa and T24 cells initiates within c-sis exon 1 and may in fact
be identical to a 3.0 kb mRNA species expressed in vascular
endothelial cells (29). The 2.6 kb mRNA species seems to lack
exon 1-derived sequences, which is in agreement with the results
described by Franklin et al. (28). However, as was demonstrated
for the 2.8 kb c-sis mRNA species expressed in vascular
v+=1:1 -11- PMN) +1k 'I K Ih1,1firt%nti
A B C
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insufficient exon 1-derived sequences to allow visualization by
Northern blot analysis with an exon 1-specific probe. Since
JEG-3, HeLa and T24 cells express significant levels of PDGF A
mRNA (Fig. 1D), it was even possible that the hybridization
signal at 2.6 kb was caused by a PDGF A transcript cross-hybri-
dizing with the c-sis probe.
To examine whether the 2.6kbmRNA expressed in JEG-3 cells
starts at the 3'-end of c-sis exon 1, as has been demonstrated for
the 2.8 kb c-sis mRNA expressed in endothelial cells (29), the
5'-end of the transcript was mapped by primer extension analysis,
using the exon 2-derived primer described by Fen and Daniel
(29). A single 174 nt primer extension product was found for
JEG-3 cells as well as for JAR cells (Fig. 2), which also express
only a single c-sis mRNA species of 2.6 kb (30,41). The size of
the primer extension product indicates that the 2.6 kb transcript
extends 90 nt upstream of c-sis exon 2-derived sequences.
Together with c-sis exons 2-7 and a poly A tail of 200 nt this fully
accounts for the length of the 2.6kb transcript. To check whether
these 90 nt are derived from the 3'-end of the regular c-sis exon
1, we performed nuclease SI protection analysis on RNA derived
from JEG-3 cells using a probe that extended from the 3'-end of
exon 1 to the 5'-end of exon 4 (as depicted in Fig. 3A). RNA from
phorbol ester-treated K562 cells, which express only the 3.5 kb
transcript, was used as a control. As expected, all c-sis-derived
sequences present in the nuclease S1 probe were protected by the
3.5 kb transcript expressed in K562 cells, which resulted in a
435 nt long fragment (Fig. 3B). Surprisingly, the nuclease SI
probe protected only a 255 nt long sequence in RNA from JEG-3
cells (Fig. 3B), instead of a 345 nt long region that was expected
if the 2.6 kb mRNA would start at the 3'-end of exon 1. In fact,
in JEG-3 RNA, the protected region initiates exactly at the
boundary between exons 1 and 2. Thus, the combined results of
the Northern blot, primer extension and nuclease S I experiments
indicate that the choriocarcinoma cell line JEG-3 expresses a
2.6 kb c-sis mRNA species that extends 90 nt upstream of c-sis
exon 2-derived sequences and initiates at an alternative exon.
The 2.6 kb c-sis mRNA species contains the code for a
novel PDGF-B-like protein
In order to identify the alternative c-sis exon, we decided to isolate
a cDNA corresponding to the 5'-end of the 2.6 kb transcript by a
cDNA amplification method (single-strand-ligation-of-cDNA or
SLIC-PCR; 39). First strand cDNA was synthesized from JEG-3
RNA using a c-sis exon 6-derived primer. A single stranded
adapter was ligated to the 3'-end and the cDNA was amplified in
a polymerase chain reaction using a nested c-sis exon 5-derived
primer and an oligonucleotide complementary to the adapter. The
resulting cDNA was cloned into a pGEM vector yielding clone
pCORD1 and its nucleotide sequence was determined (Fig. 4A).
The cDNA clone contains the previously described c-sis exons
2-5 (3-5) and, in addition, a novel 55 bp sequence located
immediately upstream of exon 2. The novel sequence contains
three ATG codons, two of which are in frame with the code for
the PDGF B chain precursor that continues in exon 2. The first
ATG is followed by a stop codon in exon 2 and initiates an open
reading frame of only 20 codons. The third ATG codon perfectly
matches the criteria of a consensus translation initiation site
according to Kozak (42; see Fig. 4B). Translation from this codon
would result in the synthesis of a PDGF B-like polypeptide that
contains the tripeptide met-gly-leu at its amino-terminus, fol-
- Re.exor
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Figure 3. Nuclease S1 analysis of the 2.6 kb c-sis mRNA. (A) Schematic
representation of the probe that was used for the nuclease SI analysis. c-sis
exons 1-7 are boxed. The probe is indicated by the black bar. (B) Total RNA
derived from TPA-treated K562 cells and JEG-3 cells was hybridized with the
32P-labeled nuclease S1 probe (Fig. 3A). The RNA-DNA hybrids were treated
with nuclease S1 and the protected fragments were analysed by electrophoresis
in a sequencing gel. The sizes of the protected fragments were determined by
comparison with a parallel sequence ladder generated by dideoxy nucleotide
sequence analysis of the nuclease SI probe. Arrows indicate the positions of the
protected fragments and the position of the predicted 345 nt fragment.
lowed by amino acids that are encoded by exon 2. As a result, the
signal peptide is replaced by an N-terminus harbouring three
negatively charged residues within the first ten amino acids.
The alternative c-sis exon la is preceded by a
functional promoter and coincides with a pronounced
DH region in c-sis intron 1
Earlier, we and others localized very pronounced DH sites within
c-sis intron 1 in JEG-3 cells (28,30). When we used the novel 55
bp cDNA fragment as a probe for Southern blot analysis of
subcloned genomic c-sis fragments (Fig. 5A), c-sis intron 1
(subclone pAO70) was found to hybridize under highly stringent
conditions (Fig. SB). Ultimately, the hybridizing region could be
localized on a 1.4 kb PvuU fragment (Fig. SC), of which the
nucleotide sequence was partly determined (Fig. 6). Indeed, the
PvuII fragment contains the same 55 bp sequence as is present in
the 5'-end of c-sis cDNA clone pCORD1. The 55 bp sequence is
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AGAGAGAGAGAGAGACTGACTGAGCAGGAATGGTGAGATGTTTATCATGGGCCTC]
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G D P I P E B L Y E M L S D H S I R S F D D
G T P F P R S F M R C *
200
TCTCCAACGCCTGCTGCACGGAGACCCCGGAGAGGAAGATGGGGCCGAGTTGGACCTGAACATGACCCGCTCCCACTCTGGAGGCGAGCTGGAGAGCTTGGCTCGTGGAAGAAGGAGCCT
L Q R L L H G D P G E E D G A E L D L N M T R S H S G G E L E S L A R G R R S L
250 300 350
GGGTTCCCTGACCATTGCTGAGCCGGCCATGATCGCCGAGTGCAAGACGCGCACCGAGGTGTTCGAGATCTCCCGGCGCCTCATAGACCGCACCAACGCCAACTTCCTG;GTGTGGCCGCC
G S L T I A E P A M I A B C K T R T E V F E I S R R L I D R T N A N F L V W P P
400 450
CTGTGVRGAGGTGCAGCGCTGCTCCGGCTGCTCAACAACCGCAACGTGCAGTGCCGCCCCACCCAGGRPCAGCPRCGACCTVTCCAGGTGAGAAAGATCGAGATTGGlCGGAAGAAGCC
C V E V Q R C S G C C N N R N V Q C R P T Q V Q L R P V Q V R K I E I V R K K P
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I F K K A T V T L E D H L A C K C E T V A A A R P V T R S P G G S Q E Q R
B
first Met codon
second Met codon
third Met codon
consensus startcodon
-3 +4
GGA ATG G
III
III
GAG ATG T
III
III
ATC ATG G
1.1 IIIICC III
ACC ATG G
Figure 4. Nucleotide sequence and deduced amino acid sequence of c-sis cDNA clone pCORD1. (A) The 3' boundary of the novel 55 bp long sequence is indicated
by parentheses. ATG codons in the novel sequence are underlined. The consensus translation initiation site is double underlined. Translation termination codons are
indicated by asterisks. The sequence complementary to the exon 5-derived oligonucleotide used in the SLIC-PCR procedure is shown in bold. (B) Alignment of the
ATG codons in the novel 55 bp sequence with the consensus translation initiation site according to Kozak (42).
followed by a consensus 5'-splice site. The 5'-end of the
alternative exon, which we refer to as exon la, was localized at
90 bp upstream of its 3'-end, according to the results ofthe primer
extension experiment (Fig. 2). The presumptive transcription
start site of the 2.6 kb transcript is not preceded by a TATA box
and maps at a remarkable sequence, where a polypurine stretch
(dGdA)7 switches to an alternating purine/pyrimidine stretch
(dGdPy) 1.
To test whether exon 1 a is preceded by a functional promoter,
a genomic DdeI fragment containing the region between
positions -191 to +28 relative to the presumptive transcription
start site (see also Fig. 6) was cloned in front of the chlorampheni-
col acetyltransferase (CAT) gene and assayed for promoter
activity in JEG-3 cells (Fig. 7). In the sense orientation
(pAltsis(s)CAT), the 0.22 kb DdeI fragment has activity that is
-15-fold lower than the activity of the regular c-sis promoter (psis
-1 12/+43CAT), whereas in the antisense orientation (pAltsis(a)
CAT) it displays only background activity.
To examine whether the alternative exon la coincides with a
DH site previously found in JEG-3 cells (28,30), we decided to
map the boundaries of this DH site more precisely. By Southern
blot analysis of a 3.3 kb KpnI fragment we could localize the DH
site between 1.9 and 1.3 kb upstream of the 3'-KpnI site (Fig. 8),
which corresponds exactly with the positions of the alternative
exon la and its immediate upstream region (see also Fig. SA). We
could also detect two small protected regions within the DH site,
which may result from the binding of specific trans-acting
factors. Our results indicate that the alternative exon la is
preceded by a functional promoter and coincides exactly with a
DH site in intron 1, at -4 kb downstream of the transcription start
site of the regular 3.5 kb c-sis mRNA.
DISCUSSION
The human c-sis/PDGF B gene uses several different ways to
regulate its expression. Transcription of the gene is regulated in
a cell type- and developmental stage-specific manner and can be
influenced by several extracellular agents (reviewed in 43,44).
Translation can be inhibited up to 40-fold by the 1 kb long
GC-rich leader of the 3.5 kb c-sis mRNA (10-12). Expression of
a 2.8 kb c-sis mRNA that initiates at the 3' end of exon 1 may
provide a means to escape from the translation inhibitory effect
ofthe leader sequence (29). The 3.5 kb c-sismRNA has a variable
stability depending on the cell type in which it is expressed (e.g.
45,46). All these regulatory mechanisms have in common that
they modulate the expression level of the PDGF B gene, but do
not affect the code for the PDGF B chain precursor. We now
demonstrate a completely new expression pathway for the human
c-sis gene: initiation of transcription at an alternative promoter
located in intron 1, at 4 kb downstream of the transcription start
site of the 3.5 kb transcript, yields a 2.6 kb c-sis mRNA that lacks
the GC-rich leader. Sequence analysis of a cDNA that corre-
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Figure 5. Localization of the alternative c-sis exon la. (A) Restriction enzyme map of c-sis intron 1 and flanking regions. Genomic subclones of the human c-sis gene
are indicated by stippled boxes. Exons are indicated by E. El indicates the genomic probe that was used for DH site mapping. The horizontal bracket indicates the
region of DNase-I-hypersensitivity (see also Fig. 8). H, HindHI; B, BamHI; E, EcoRI; K, KpnI; X, XhoI; P, Pvull. (B) Inserts from the genomic c-sis gene subclones
depicted in Figure 5A were examined by Southern blot analysis using the altemative exon la as a probe. (C) Genomic subclone pAO70 was examined in more detail
by Southern blot analysis of restriction enzyme digestions using the alternative exon I a as a probe.
50
cagctgcgctggcttccaggagggcgagtcccactgtcacgtgacgcgtctggcc r.
100
L tcagcacacttcttccgggaaagagtgaagggccccactgccctttgccatccagcttcctctgg
150 . 200
ctttgctaatggccctaggggcgaggagaccaactgctggaatcccagagccctggaggtgtgcaagggcaggtcaaacagaatttggaggatctggtgcaagagccaggaagagagaga
*250 . 4 300 . 350
gagagaGTGTGTG TGTGCGCGCGCATCTGA] G A_GG C CGCAGGAA TGGTGAGATGTATCATGGGCCTCgt&agtactccacgtcttgtc
400 . 450
ttcccctccccacattgaggagcctcttctgtgacaactcttcctatgttctggtttatttcattgtttattacctgctttctctactggagtgtcaaccccattagagagctttcctcc
500
tggtccccacttttagaacagtgccagagcctgtggacaatcagtaact
Figure 6. Nucleotide sequence of the altemative c-sis exon la and its flanking regions. The sequence starts at the Pvull site immediately upstream of the altemative
exon la (see also Fig. 5A). Exon la sequences are in upper case. The presumed transcription initiation site of the 2.6 kb c-sis mRNA is indicated by an asterisk. The
5' end of cDNA clone pCORDl is indicated by an arrow. ATG codons in exon la are underlined. The consensus translation initiation site according to Kozak (42)
is underlined twice. The 0.22 kb DdeI fragment that displays promoter activity in a transient reporter gene assay is indicated by brackets (see also Fig. 7).
sponds with the 5' end of the 2.6 kb mRNA indicated that the
transcript contains the regular c-sis exons 2-5. By Northern blot
analysis with exon-specific probes we could show that it also
contains sequences derived from c-sis exon 6 and from the 5' and
3' parts of exon 7. Primer extension analysis showed that the
alternative exon la is 90 bp long, which in combination with the
regular exons 2-7 fully accounts for the length of the 2.6 kb
transcript. Thus, the only difference between the 3.5 and 2.6 kb
c-sis transcripts is the origin of their first exon sequences.
The alternative c-sis expression pathway that is followed in
JEG-3 cells may have important qualitative and quantitative
consequences for the gene product. The 5'-untranslated sequence
of the 2.6 kb c-sis mRNA is maximally 81 nt long, has a GC
content of only 52% and is not expected to adopt extensive
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Figure 7. Transient reporter gene analysis of the regular and alternative c-sis gene promoter in JEG-3 cells. Cells were electropermeated with a mixture of pCHl 10
and the indicated CAT constructs as described in Materials and Methods. Aliquots of lysate normalized to mean ,B-galactosidase activity were tested for CAT activity.
CA, chloramphenicol; acetyl-CA, 1- and 3-acetyl-chloramphenicol. All data are means from two to four independent electropermeations.
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Figure 8. Fine mapping of the DH site located in the center of c-sis intron 1.
Nuclei from JEG-3 cells were treated with increasing amounts of DNase I.
Chromosomal DNA (25 ,ug) was digested with KpnI and subjected to Southern
blot analysis. The DNA was hybridized with the genomic probe depicted in
Figure 5. DNase I concentrations: (-) no DNase I added; (a) 42 U/ml; (b) 84 U/ml;
(c) 168 U/ml; (d) 294 U/ml; (e) 462 U/ml; (f) 672 U/ml; (g) 924 U/mi.
secondary structures. Therefore, as was previously predicted for
the 2.8 kb c-sis mRNA expressed in vascular endothelial cells
(29), the absence of the GC-rich leader sequence may result in the
synthesis of significant levels of protein product, even from
relatively low levels of mRNA. Much more importantly,
translation from the 2.6 kb c-sis mRNA may generate a novel
PDGF B-like protein product. Exon la contains three ATG
codons, of which the first one would initiate a peptide of only 20
amino acids. The third ATG codon, which is in frame with the
code for the PDGF B chain precursor that continues in exon 2, has
the best match with the consensus translation start site according
to Kozak (42). Initiation of translation at the third ATG codon is
quite possible given the fact that translation of the 3.5 kb c-sis
mRNA initiates even at the fourth ATG codon, which also meets
the criteria of the Kozak consensus sequence (34). The regular
exon 1 codes for the signal peptide of the PDGF B chain
precursor, which is essential for its translocation to the ER.
Translation from the third ATG codon of the 2.6 kb mRNA would
generate a polypeptide containing five acidic residues among its
first 20 amino acids. Since this acidic N-terminus does not
constitute a signal peptide, we predict that the alternative
polypeptide is synthesized at 'free' cytoplasmic ribosomes. The
regular PDGF B chain precursor dimerizes in the ER and is
proteolytically processed in the Golgi system yielding a 24-30
kDa dimeric protein that is secreted or remains membrane
associated (13-17). In contrast, the product of the 2.6 kb c-sis
mRNA species is expected to be a monomeric 25 kDa polypep-
tide that is initially located in the cytoplasm. The PDGF B chain
precursor has been shown to contain a functional nuclear
localization signal (NLS) in its exon 6-derived sequence (47).
The NLS is usually masked, due to the rapid translocation of the
PDGF B chain precursor into the ER, and is subsequently
removed by proteolytic processing in the ER. In the absence of a
signal peptide, the NLS may target the product of the 2.6 kb c-sis
mRNA to the cell nucleus.
The alternative exon la is preceded by a functional promoter
that coincides exactly with a very pronounced DH site in JEG-3
cells. DH sites are thought to represent nucleosome-free regions
that often correspond with sites of specific DNA-protein
interactions (48). The DH site at the alternative promoter extends
over 600 bp, which indicates that three nucleosomes are absent or
disrupted. The nuclease S I and primer extension analyses
showed that the 2.6 kb c-sis mRNA extends 90 nt upstream of the
exon 2-derived sequence, which places the transcription initiation
site 90 bp upstream ofthe 3' end ofexon la. The transcription start
site coincides with the switch from a (GA)7-repeat to a
(GPy) II-repeat (Fig. 6) and is not preceded by a consensus TATA
box. A (GA) 12-repeat is located within exon Ia and starts at 64 bp
upstream of the 3' end of the exon. Recently, binding of a GAGA
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transcription factor was shown to disrupt nucleosomes at a
heat-shock promoter (49). A similar mechanism may be respon-
sible for the generation of the DH site at exon la. Two
DNase-I-footprints could easily be distinguished within the
nucleosome-free region (Fig. 8), which may reflect specific
DNA-protein interactions at the alternative promoter.
We are currently focusing on the structural and functional
characterization of the putative protein product of the 2.6 kb c-sis
mRNA. The regular c-sis gene product has transforming activity
(50-52) and is associated with several tumor species (reviewed
in 43). Whether the putative PDGF B-like protein product of the
2.6 kb c-sis mRNA has transforming activity is questionable, as
it was shown that mutagenesis of the signal peptide of the v-sis
gene resulted in a nuclear localization of the protein product and
a loss of transforming activity (53). There is accumulating
evidence that some growth factors exert their role in mitogenesis
partly in the nucleus (e.g. 54,55). Whether a similar phenomenon
holds true for the putative product of the 2.6 kb c-sis mRNA
remains to be determined.
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